Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
Menu
NET Nurse
Donate
What are NETs?
Patients & Carers
Healthcare Professionals
Get Involved
NET Nurse
Donate
What are NETs?
  • What are Neuroendocrine Cancers?
  • What are Pheos & Paras?
  • NET Symptoms
  • Causes
  • Treatments
  • Grades
National Action Plan
Patients & Carers
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • Patient Stories
  • Share your Story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
National Action Plan
Healthcare Professionals
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
National Action Plan
Get Involved
  • Advocate for Us
  • Share your Story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
National-Action-Plan-1.png
NET Nurse
Donate

Home » General » Lanreotide rejected by PBAC for listing on PBS for non-functional GEP NETs

Lanreotide rejected by PBAC for listing on PBS for non-functional GEP NETs

  • January 19, 2017
After the November meeting the PBAC rejected the submission for listing of Lanreotide for non functional GEP NETs.

According to the PBAC "Subsequent decisions not to recommend" document,  The PBAC did not recommend the listing of lanreotide for the treatment of non-functional GEP NETs on the basis of unfavourable and uncertain cost-effectiveness at the price proposed by the sponsor.

The Unicorn Foundation CEO Simone Leyden and patient Peter McMenamin had the opportunity to present the patient case for Lanreotide at a consumer hearing to the PBAC on November 1 in Brisbane, we are very grateful to Peter who did an outstanding job representing NET Cancer patients and telling about his experience on the drug and how it was effective for him.

According to the above mentioned document, The PBAC acknowledged and welcomed the many consumer comments received from people living with non-functional GEP-NETs and the input from the Unicorn Foundation. In addition, representatives of the PBAC met with the Unicorn Foundation prior to the PBAC meeting to discuss the clinical place, benefits and side effects of lanreotide for the requested patient population. The Committee recognised the strong support for subsidised access to lanreotide for this condition. 

 According to IPSEN the drug sponsor Whilst Ipsen is disappointed with the decision, we remain committed to working with PBAC to ensure this important indication is made available to Australian patients with GEP-NETs.

We are also committed to ensuring that NET Cancer patients can access drugs that are considered standard care and will keep you updated on any progress. 

To view the full document please see below. 

 https://neuroendocrine.org.au/wp-content/uploads/2020/03/subsequent-decisions-not-to-recommend-2016-11.pdf

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Online survey for NET patients

September 26, 2023

Medicines Australia PharmAus event in Canberra

September 26, 2023

INCA Annual Summit 2023

September 26, 2023

Have your say on #EndGenderBias in Australia’s healthcare system

September 19, 2023
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousNew online chat sessions for NET Patients
NextRegistered charity tickNext

Related Posts

INCA Annual Summit 2023

The International Neuroendocrine Cancer Alliance (INCA) Annual Summit was held in Bologna on the 11 & 12 September 2023. It was such a productive 2

CNSA Annual National Congress 2023

CNSA Annual National Congress 2023 The 25th Cancer Nurses Society of Australia’s (CNSA) Annual Congress was held at the Adelaide Convention Centre June 14th – 16th 2023. The

NECA Finalist as NGO of the Year in Prime Awards

We’re thrilled to be announced as one of the finalists in the NGO of The Year category in the 2022 PRIME Awards Australia. The Prime

COVID-19 Information and Resources

A note from our CEO on COVID-19: To our wonderful NET community we stand with you and alongside you as we get through this unprecedented

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness
  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness

Patients & Carers

  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS

Healthcare Professionals

  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources

Get Involved

  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2023 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin

What's on?

How to identify a neuroendocrine cancer when it’s not part of the typical line up. A RACGP & ACN CPD accredited course.

Share this course with your healthcare professional so they can enrol in this free online course and learn more about how to diagnose and treat NETs in general practice.

Learn More